Sirio Pharma Co (SZSE:300791) Cash-to-Debt : 0.42 (As of Mar. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Sirio Pharma Co Cash-to-Debt?

Cash to Debt Ratio measures the financial strength of a company. It is calculated as a company's cash, cash equivalents, and marketable securities divide by its debt. Sirio Pharma Co's cash to debt ratio for the quarter that ended in Mar. 2024 was 0.42.

If Cash to Debt ratio is less than 1, the company cannot pay off its debt using the cash in hand. Here we can see, Sirio Pharma Co couldn't pay off its debt using the cash in hand for the quarter that ended in Mar. 2024.

The historical rank and industry rank for Sirio Pharma Co's Cash-to-Debt or its related term are showing as below:

SZSE:300791' s Cash-to-Debt Range Over the Past 10 Years
Min: 0.17 Med: 1.35 Max: 17.61
Current: 0.42

During the past 12 years, Sirio Pharma Co's highest Cash to Debt Ratio was 17.61. The lowest was 0.17. And the median was 1.35.

SZSE:300791's Cash-to-Debt is ranked worse than
54.03% of 1873 companies
in the Consumer Packaged Goods industry
Industry Median: 0.52 vs SZSE:300791: 0.42

Sirio Pharma Co Cash-to-Debt Historical Data

The historical data trend for Sirio Pharma Co's Cash-to-Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Note: An indication of "No Debt" does not necessarily mean that the company has no debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

* Premium members only.

Sirio Pharma Co Cash-to-Debt Chart

Sirio Pharma Co Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Cash-to-Debt

Get a 7-Day Free Trial

3.96

17.61

1.43

1.69

0.54

Sirio Pharma Co Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Cash-to-Debt	Get a 7-Day Free Trial															0.49	0.46	0.49	0.54	0.42

Competitive Comparison of Sirio Pharma Co's Cash-to-Debt

For the Packaged Foods subindustry, Sirio Pharma Co's Cash-to-Debt, along with its competitors' market caps and Cash-to-Debt data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sirio Pharma Co's Cash-to-Debt Distribution in the Consumer Packaged Goods Industry

For the Consumer Packaged Goods industry and Consumer Defensive sector, Sirio Pharma Co's Cash-to-Debt distribution charts can be found below:

* The bar in red indicates where Sirio Pharma Co's Cash-to-Debt falls into.

Sirio Pharma Co Cash-to-Debt Calculation

This is the ratio of a company's Cash, Cash Equivalents, Marketable Securities to its debt. The debt includes the Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation. This ratio measures the financial strength of a company. This ratio is updated quarterly.

Sirio Pharma Co's Cash to Debt Ratio for the fiscal year that ended in Dec. 2023 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	735.143	/	(64.044	+	1305.201)
	=	0.54

Sirio Pharma Co's Cash to Debt Ratio for the quarter that ended in Mar. 2024 is calculated as:

Cash to Debt Ratio	=	Cash, Cash Equivalents, Marketable Securities	/	Total Debt
	=	Cash, Cash Equivalents, Marketable Securities	/	(Short-Term Debt & Capital Lease Obligation	+	Long-Term Debt & Capital Lease Obligation)
	=	603.713	/	(88.742	+	1367.5)
	=	0.41

Sirio Pharma Co (SZSE:300791) Cash-to-Debt Explanation

If Cash to Debt ratio is greater than 1, the company can pay off its debt using the cash in hand. If it is smaller than 1, it means the company has more debt than the cash in hands. In this case, it is important to look the the company's Interest Coverage. Ben Graham requires that a company must have an Interest Coverage of at least 5.

Sirio Pharma Co Cash-to-Debt Related Terms

Thank you for viewing the detailed overview of Sirio Pharma Co's Cash-to-Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Sirio Pharma Co (SZSE:300791) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Consumer Defensive » Consumer Packaged Goods » Sirio Pharma Co Ltd (SZSE:300791) » Definitions » Cash-to-Debt

Traded in Other Exchanges

N/A

Address

No. 83, Taishan Road, Guangdong Province, Shantou, CHN, 515057

Website

http://www.siriopharm.com

Sirio Pharma Co Ltd is engaged in the research and development, production, sales and technical services of nutrition and health food, food production, sales, import and export of goods.

Executives

Zheng Li Qun	Directors, executives
Yang Rui	Directors, executives

Sirio Pharma Co (SZSE:300791) Headlines

No Headlines